# Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

> **NCT00140556** · EARLY_PHASE1 · COMPLETED · sponsor: **David M. Brizel, MD** · enrollment: 28 (actual)

## Conditions studied

- Head and Neck Cancer
- Pharynx Cancer

## Interventions

- **RADIATION:** Chemoradiotherapy
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00140556
- **Lead sponsor:** David M. Brizel, MD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-05
- **Final completion:** 2010-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2013-01-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140556, "Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00140556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*